insights_auto
Pse është rritur AXGN 2,61%?
Zhytu më thellëchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
50,02 US$
arrow_upward
+2,61%(+1,27) 1D
50,00 US$
arrow_downward
-0,04% (-0,020)bedtimeJashtë orarit
Mbyllur: 6 nën, 4:00:01 m.d., GMT-5 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AXGN...
Hap
48,55 US$
I lartë
50,29 US$
I ulët
48,14 US$
Kapitalizimi i tregut
2,99 mld
Vëllimi mesatar
1,79 mln
Vëllimi
1,67 mln
Maksimumi 52-javor
52,91 US$
Minimumi 52-javor
23,00 US$
Fitimet për aksion
-0,68 US$
Beta
1,21
Aksionet në qarkullim
59,73 mln
Numri i punonjësve
622
Hap
48,55 US$
I lartë
50,29 US$
I ulët
48,14 US$
Kapitalizimi i tregut
2,99 mld
Vëllimi mesatar
1,79 mln
Vëllimi
1,67 mln
Maksimumi 52-javor
52,91 US$
Minimumi 52-javor
23,00 US$
Fitimet për aksion
-0,68 US$
Beta
1,21
Aksionet në qarkullim
59,73 mln
Numri i punonjësve
622
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Yahoo! Finance Canada
·
22 minuta më parë
VITL,NTHI,TRIN,SRAD,HERZ,EFOR,FFIN,NXRT,AVBC,BBSI,CULP,BLCO,VSNT,VIRC,GRNT,SSP,GAIA,CSPI,AFCG,AWRE,APCX,KLTR,BETR,AUBN | Stock Prices | Quote Comparison - Yahoo Finance
The Motley Fool
·
44 minuta më parë
No Matter What Happens to the S&P 500 in November, These 3 Dividend Stocks Belong in Your Portfolio
Seeking Alpha
·
2 orë më parë
The Nasdaq Is Toast: QQQ Could Go 40% Lower. Here's How, And What Could Stop It. (QQQ)
Bloomberg.com
·
1 ditë më parë
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Profili
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Rreth AxoGen, Inc Common Stock
Drejtori ekzekutiv-
Punonjësit622
Themeluar më2002
SeliaAlachua, Florida, Shtetet e Bashkuara të Amerikës
SektoriHealth Care
IndustriaMedical device
Uebsajtiaxogeninc.com